Positron Emission Tomography in Hodgkin Lymphoma Patients Undergoing Curative-Intent Treatment

ID: 27-4 mar 2016

Type of Content: Guidelines & Advice, Evidence Summary

Document Status: Current

Authors:

T. Baetz, J. Dudebout, J. Salerno, J. Dobranowski, E. Eisenhauer, D. Langer, L. Jimenez-Juan, U. Metser, M. O'Malley, A. Singnurkar

Guideline Objective

To provide an evidence summary on PET imaging in the care of HL patients undergoing first-line curative-intent treatment.

Patients aged ≥16 years with HL at any stage of disease who are undergoing first-line curative-intent treatment.

Clinicians involved in the care of HL patients.

The following research questions were developed to direct the search for available evidence on HL:

What is the ideal timing and reporting of FDG-PET/CT or FDG-PET?
- For HL patients during treatment? (i.e., interim PET) i. Interim defined as scans performed during first-line curative-intent treatment (i.e., single modality or combined-modality therapy)
- For HL patients following chemotherapy ± radiation therapy? (i.e., end-of-therapy or final PET) i. End-of-treatment PET defined as scans performed immediately upon the completion of treatment (i.e., immediate post-treatment or end of treatment).
What are the clinical activities that should be performed following an end-of-therapy PET(+) scan?
- Clinical activities are defined as the number of PET scans, number of CT scans, biopsy, and change in treatment.